Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin

Advanced Drug Delivery Reviews

Volumn 61, Issue 13, 2009, Pages 1189-1192

  Davis, Mark E ^a  

^a California Institute of Technology   (United States)

Author keywords

Camptothecin; Clinical trials; Cyclodextrin polymer; IT 101

Indexed keywords

CAMPTOTHECIN; CAMPTOTHECINS; CLINICAL TRIAL; CLINICAL TRIALS; CYCLODEXTRIN POLYMER; DESIGN AND DEVELOPMENT; HALF LIVES; IT-101; POLYMER CHAINS; POLYMER CONJUGATE; TUMOR CELLS;

ANIMALS; BODY FLUIDS; CHARGE TRAPPING; INDUSTRIAL CHEMICALS; LIGANDS; NANOPARTICLES; POLYMERS; TUMORS; ZETA POTENTIAL;

FUNCTIONAL POLYMERS;

CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLODEXTRIN; IRINOTECAN; IT 101; NANOPARTICLE; PLACEBO; POLYMER; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SYNTHESIS; HALF LIFE TIME; HUMAN; KIDNEY CANCER; KIDNEY CLEARANCE; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; TUMOR CELL; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; CYCLODEXTRINS; DELAYED-ACTION PREPARATIONS; DRUG DESIGN; HALF-LIFE; HUMANS; NANOPARTICLES; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 70349992906     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.05.005     Document Type: Review

References (17)

1. Davis M.E., Chen Z., and Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev., Drug Discov. 7 (2008) 771-782
2. Davis M.E., and Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev., Drug Discov. 3 (2004) 1023-1035
3. Gonzalez H., Hwang S.J., and Davis M.E. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug. Chem. 10 (1999) 1068-1074
4. Davis M.E., Pun S.H., Bellocq N.C., Reineke T.M., Popielarski S.R., Mishra S., and Heidel J.D. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr. Med. Chem. 11 (2004) 179-197
5. Cheng J., Khin K.T., Jensen G.S., Liu A., and Davis M.E. Synthesis of linear, β-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug. Chem. 14 (2003) 1007-1017
6. Cheng J., Khin K.T., and Davis M.E. Antitumor activity of β-cyclodextrin polymer-camptothecin conjugates. Mol. Pharm. 1 (2004) 183-193
7. Schluep T., Hwang J., Hildebrandt I.J., Czerin J., Choi C.H.J., Alabi C.A., Mack B.C., and Davis M.E. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc. Nat. Acad. Sci. USA 106 (2009) 11394-11399
8. Jorgensen K.E., and Moller J.V. Use of flexible polymers as probes of glomerular pore size. Am. J. Physiol. 236 (1979) F103-F111
9. Schluep T., Cheng J., Khin K.T., and Davis M.E. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother. Pharmacol. 57 (2006) 654-662
10. Schluep T., Hwang J., Cheng J., Heidel J.D., Bartlett D.W., Hollister B., and Davis M.E. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res. 12 (2006) 1606-1614
11. Numbenjapon T., Wang J., Colcher D., Schluep T., Davis M.E., Duringer J., Kretzner L., Yen Y., Forman S.J., and Raubitschek A. Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin. Cancer Res. 15 (2009) 4365-4373
12. Jensen G.S., Hwang J., and Schluep T. Antitumor activity of IT-101, a cyclodextrin-containing polymer-camptothecin nanoparticle, in combination with various anticancer agents in human ovarian cancer xenografts. AACR Annual Meeting (2008) 08-AB-7402-AACR
13. Oliver J.C., Yen Y., Synold T.W., Schluep T., and Davis M.E. A dose-finding pharmacokinetic study of IT-101, the first de novo designed nanoparticle therapeutic, in refractory solid tumors. ASCO Annual Meeting (2008) 14538
14. Dreher M.R., Liu W., Michelich C.R., Dewhirst M.W., Yuan F., and Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 98 (2006) 335-344
15. Schluep T., Gunawan P., Ma L., Jensen G.S., Duringer J., Hinton S., Richter W., and Hwang J. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin. Cancer Res. 15 (2009) 181-189
16. Hwang J., Rodgers K., Oliver J.C., and Schluep T. α-Methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int. J. Nanomed. 3 (2008) 359-371
17. Lim C.-J., Hwang J., Gunawan P., Davis M.E., and Schluep T. Enhanced uptake of cyclodextrin-based polymer nanoparticles by targeting with LHRH peptide. AAPS Annual Meeting (2007)